Foreign media news on April 15: The Ukrainian
Express | Significantly prolongs the lives of prostate cancer patients, Novartis targeted radiotherapy reaches phase 3 clinical endpoint
Time of Update: 2021-04-21
▎Editor of WuXi AppTec's content team On March 23, Novartis announced that its potential "first-in-class" targeted radioligand therapy (RLT) 177Lu-PSMA-617 is in the treatment of stage 3 of patients with advanced prostate cancer.
AstraZeneca announces Phase 3 data for new crown vaccine
Time of Update: 2021-04-20
On March 25, local time, AstraZeneca's official website announced that the preliminary analysis results of the phase III clinical trial of the new crown vaccine AZD1222 were consistent with the interim analysis results announced on March 22.
Phase 3 of LAG-3 antibody reached the primary endpoint!
Time of Update: 2021-04-20
-3 antibody relatlimab and anti-PD-1 antibody Opdivo (nivolumab) can be used in the treatment of newly treated patients with metastatic or unresectable melanoma. In Phase 2/3 clinical trials, the primary endpoint of progression-free survival
China's latest consensus on diagnosis and treatment of central nervous system infections released, 3 minutes to focus
Time of Update: 2021-04-19
Recommendations: ➤ For patients with high suspicion of intracranial infection, CT or MRI is recommended to assist in diagnosis and treatment (medium level, strong recommendation).
quarter of 2021, 3 new drugs listed in urgent need of clinical overseas new drugs
Time of Update: 2021-04-19
In China, the drug's marketing application was accepted by CDE in February 2021, and was subsequently included in the priority review for the indication β-thalassemia.
Pfizer announces Phase 3 clinical results of abrocitinib, a new-generation oral JAK1 inhibitor
Time of Update: 2021-04-19
(100mg, 200mg, once a day, orally), positive control drug dupilumab (300mg, baseline 600mg loading dose, once every 2 weeks, subcutaneous injection), placebo efficacy and safety, all patients received topical therapy.
3 minutes to focus on blood pressure management in patients with acute ischemic stroke and heart disease|Guideline consensus
Time of Update: 2021-04-18
The annual incidence of stroke in my country is 250/100,000, and the annual incidence of coronary heart disease events is 50/100,000. Stroke and coronary heart disease
The detailed data of the Phase 3 clinical trial of Kexing inactivated vaccine is announced
Time of Update: 2021-04-18
The results of this test showed that the protective effect of two doses of CoronaVac on symptomatic COVID-19 reached 50.
Both pictures and texts, teach you how to treat "hemorrhoids" under endoscopy (3)
Time of Update: 2021-04-18
and prolapse); 2. Hemorrhoids in stage I-III are ineffective in diet and drug treatment; 3. Recurrence after internal hemorrhoid surgery, but not after repeated anal surgery Surgery again; 4. Fear of surgery, unwilling
The results of the first phase 3 study of the first-line immunotherapy for gastric cancer in China
Time of Update: 2021-04-18
> The Chinese subgroup data of the CheckMate-649 study strengthens our confidence in promoting the continuous development of gastric cancer and gastroesophageal junction cancer immunotherapy, and is expected to comprehensively
Pfizer abrocitinib and Xeljanz review delayed by FDA for 3 months
Time of Update: 2021-04-18
In addition, the FDA has extended the review period of the supplementary new drug application (sNDA) for the oral anti-inflammatory drug Xeljanz/Xeljanz XR (tofacitinib, tofacitinib) for the treatment of adult patients with active ankylosing spondylitis (AS) by 3 months.
The state takes action! The medical insurance reform that benefits more than 300 million employees will usher in a big move
Time of Update: 2021-04-18
of current employees are still credited to their personal accounts, and all unit payments are credited to the overall fund. This means that the “three-to-seven percent” of the employer's payment part mentioned above will become
When Me-too becomes We-too, how should China take the road of innovative drugs?
Time of Update: 2021-04-18
909 chemical innovation drug (class 1 new drugs) registration application acceptance numbers, and 835 approved acceptance numbers (on average, there are 2 acceptance numbers for a variety, which is equivalent to more than 400 new drugs).
BeiGene Announces Global Phase 3 Clinical Interim Analysis Results of Baizean® in the Treatment of Second- and Third-Line Non-Small Cell Lung Cancer
Time of Update: 2021-04-18
On April 13, BeiGene (Nasdaq code: BGNE; Hong Kong Stock Exchange code: 06160) announced its anti-PD-1 antibody Bazeran® at the American Association for Cancer Research (AACR) 2021 annual meeting (Tilelizumab
